Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Conticello, Concetta, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Sapienza, Giuseppe, Leotta, Valerio, Parisi, Marina Silvia, Markovic, Uros, Garibaldi, Bruno, Leotta, Salvatore, Cotzia, Emilia, Innao, Vanessa, Mannina, Donato, Neri, Santo, Musso, Maurizio, Scalone, Renato, Cangialosi, Clotilde, Acquaviva, Francesco, Cardinale, Giovanni, Merenda, Anxur, Maugeri, Cinzia, Uccello, Giuseppina, Poidomani, Massimo, Longo, Giuseppe, Carlisi, Melania, Tibullo, Daniele, Di Raimondo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617295/
https://www.ncbi.nlm.nih.gov/pubmed/31248142
http://dx.doi.org/10.3390/jcm8060877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617295/
https://www.ncbi.nlm.nih.gov/pubmed/31248142
http://dx.doi.org/10.3390/jcm8060877

Ejemplares similares